Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200458039> ?p ?o ?g. }
- W4200458039 endingPage "17812" @default.
- W4200458039 startingPage "17795" @default.
- W4200458039 abstract "The 3,9-diazaspiro[5.5]undecane-based compounds 2027 and 018 have previously been reported to be potent competitive γ-aminobutyric acid type A receptor (GABAAR) antagonists showing low cellular membrane permeability. Given the emerging peripheral application of GABAAR ligands, we hypothesize 2027 analogs as promising lead structures for peripheral GABAAR inhibition. We herein report a study on the structural determinants of 2027 in order to suggest a potential binding mode as a basis for rational design. The study identified the importance of the spirocyclic benzamide, compensating for the conventional acidic moiety, for GABAAR ligands. The structurally simplified m-methylphenyl analog 1e displayed binding affinity in the high-nanomolar range (Ki = 180 nM) and was superior to 2027 and 018 regarding selectivity for the extrasynaptic α4βδ subtype versus the α1- and α2- containing subtypes. Importantly, 1e was shown to efficiently rescue inhibition of T cell proliferation, providing a platform to explore the immunomodulatory potential for this class of compounds." @default.
- W4200458039 created "2021-12-31" @default.
- W4200458039 creator A5001593002 @default.
- W4200458039 creator A5002633666 @default.
- W4200458039 creator A5004224346 @default.
- W4200458039 creator A5010220586 @default.
- W4200458039 creator A5011101034 @default.
- W4200458039 creator A5017298756 @default.
- W4200458039 creator A5020576630 @default.
- W4200458039 creator A5024618143 @default.
- W4200458039 creator A5043236966 @default.
- W4200458039 creator A5054387501 @default.
- W4200458039 creator A5067070094 @default.
- W4200458039 creator A5070263300 @default.
- W4200458039 creator A5073388920 @default.
- W4200458039 creator A5074909311 @default.
- W4200458039 creator A5079565856 @default.
- W4200458039 creator A5088373447 @default.
- W4200458039 date "2021-12-15" @default.
- W4200458039 modified "2023-10-17" @default.
- W4200458039 title "Structure–Activity Studies of 3,9-Diazaspiro[5.5]undecane-Based γ-Aminobutyric Acid Type A Receptor Antagonists with Immunomodulatory Effect" @default.
- W4200458039 cites W1960644352 @default.
- W4200458039 cites W1974704485 @default.
- W4200458039 cites W1975691556 @default.
- W4200458039 cites W1977741529 @default.
- W4200458039 cites W1979099323 @default.
- W4200458039 cites W1993918716 @default.
- W4200458039 cites W1998885660 @default.
- W4200458039 cites W2002305402 @default.
- W4200458039 cites W2006052244 @default.
- W4200458039 cites W2007698198 @default.
- W4200458039 cites W2011563038 @default.
- W4200458039 cites W2012034410 @default.
- W4200458039 cites W2012480383 @default.
- W4200458039 cites W2013299143 @default.
- W4200458039 cites W2018944478 @default.
- W4200458039 cites W2022378061 @default.
- W4200458039 cites W2031168104 @default.
- W4200458039 cites W2053225896 @default.
- W4200458039 cites W2058825628 @default.
- W4200458039 cites W2060005248 @default.
- W4200458039 cites W2079953901 @default.
- W4200458039 cites W2084235789 @default.
- W4200458039 cites W2086854660 @default.
- W4200458039 cites W2097345469 @default.
- W4200458039 cites W2102377211 @default.
- W4200458039 cites W2103133373 @default.
- W4200458039 cites W2123774442 @default.
- W4200458039 cites W2131430683 @default.
- W4200458039 cites W2131561307 @default.
- W4200458039 cites W2137471600 @default.
- W4200458039 cites W2142837476 @default.
- W4200458039 cites W2149404667 @default.
- W4200458039 cites W2153516835 @default.
- W4200458039 cites W2315329852 @default.
- W4200458039 cites W2339183963 @default.
- W4200458039 cites W2429178374 @default.
- W4200458039 cites W2596688129 @default.
- W4200458039 cites W2610499911 @default.
- W4200458039 cites W2775190952 @default.
- W4200458039 cites W2786173902 @default.
- W4200458039 cites W2810911197 @default.
- W4200458039 cites W2839463924 @default.
- W4200458039 cites W2891711209 @default.
- W4200458039 cites W2894816987 @default.
- W4200458039 cites W2912139720 @default.
- W4200458039 cites W2915433992 @default.
- W4200458039 cites W2943544103 @default.
- W4200458039 cites W2947630452 @default.
- W4200458039 cites W2982081587 @default.
- W4200458039 cites W2984028394 @default.
- W4200458039 cites W2993155946 @default.
- W4200458039 cites W3036464668 @default.
- W4200458039 cites W3063814160 @default.
- W4200458039 cites W3113624232 @default.
- W4200458039 cites W3160385199 @default.
- W4200458039 cites W4238945726 @default.
- W4200458039 cites W4245486276 @default.
- W4200458039 doi "https://doi.org/10.1021/acs.jmedchem.1c00290" @default.
- W4200458039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34908407" @default.
- W4200458039 hasPublicationYear "2021" @default.
- W4200458039 type Work @default.
- W4200458039 citedByCount "4" @default.
- W4200458039 countsByYear W42004580392022 @default.
- W4200458039 countsByYear W42004580392023 @default.
- W4200458039 crossrefType "journal-article" @default.
- W4200458039 hasAuthorship W4200458039A5001593002 @default.
- W4200458039 hasAuthorship W4200458039A5002633666 @default.
- W4200458039 hasAuthorship W4200458039A5004224346 @default.
- W4200458039 hasAuthorship W4200458039A5010220586 @default.
- W4200458039 hasAuthorship W4200458039A5011101034 @default.
- W4200458039 hasAuthorship W4200458039A5017298756 @default.
- W4200458039 hasAuthorship W4200458039A5020576630 @default.
- W4200458039 hasAuthorship W4200458039A5024618143 @default.
- W4200458039 hasAuthorship W4200458039A5043236966 @default.
- W4200458039 hasAuthorship W4200458039A5054387501 @default.
- W4200458039 hasAuthorship W4200458039A5067070094 @default.
- W4200458039 hasAuthorship W4200458039A5070263300 @default.